{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30","upperLimit":"66","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The percentage of participants that have not died or had disease progression by two years. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients receive same therapy\n\nFludarabine: 30 mg/m2/day IV x 6 days\n\nMelphalan: 100 mg/m2/day IV x 1 day\n\nTotal Body Radiation: 200 cGy on Day 0\n\nCord Blood: 2 cord blood units IV","id":"OG000","title":"Fludarabine/Melphalan/TBI"}],"paramType":"NUMBER","populationDescription":"The two participants found to be ineligible after being consented and registered were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}